Advances in the Diagnosis, Prevention and Treatment of Skin Tumors

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 15 January 2025 | Viewed by 472

Special Issue Editor


E-Mail Website
Guest Editor
Department of Dermatology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
Interests: skin cancers; psoriasis; atopic dermatitis; hidradenitis suppurativa; chronic wounds; bullous diseases

Special Issue Information

Dear Colleagues,

I am delighted to announce that, along with Prof. Dr. Calin Giurcaneanu and Assistant Professor Cristina Beiu, in collaboration with the journal Medicina (ISSN 1648-9144, IF 2.4, cite score 3.3, Q1 in the “Medicine, General and Internal” category, https://www.mdpi.com/journal/medicina) I am organizing a Special Issue on “Advances in the Diagnosis, Prevention and Treatment of Skin Tumors”.

Skin cancer is not only one of the most frequent forms of cancer, but also one of the most preventable and readily recognizable. Still, in the past three decades, the incidence of no other cancer has risen as much as that of non-melanoma skin cancer, particularly cutaneous squamous cell carcinoma, while the rise in the incidence of melanoma ranked third among all types of cancer. Apart from causing significant morbidity, the mortality rates of skin cancers have remained stable or have shown a slight decrease. There are countless factors responsible for these phenomena, including genetics, increased longevity, various causes of immunosuppression, exposure to toxic agents, ozone depletion and climate change, as well as the results of prevention and early diagnosis campaigns and improved diagnostic tools. Nevertheless, efforts to improve primary prevention and detect skin cancers in an early phase need to be intensified.

Our aim is to bring together and support both clinicians and researchers to share their experiences and discuss the results of their innovative studies regarding the prevention, early diagnosis and treatment of skin tumors.

Therefore, we hope you find the topic of our Special Issue interesting and we warmly invite you to submit an original article or review. The submission deadline is 15 January 2025.

Dr. Liliana Gabriela Popa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skin cancer
  • melanoma
  • basal cell carcinoma
  • squamous cell carcinoma
  • prevention, early diagnosis
  • dermoscopy
  • medical treatment
  • surgery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 1413 KiB  
Article
Characterizing CD133 and NANOG Expression in Melanoma: Associations with Histological and Epidemiological Parameters
by Adrian-Horațiu Sabău, Raluca Niculescu, Iuliu-Gabriel Cocuz, Andreea-Cătălina Tinca, Andreea Raluca Szöke, Bianca Andreea Lazar, Diana Maria Chiorean, Corina Eugenia Budin, Alexandru Nicușor Tomuț and Ovidiu Simion Cotoi
Medicina 2024, 60(10), 1658; https://doi.org/10.3390/medicina60101658 - 10 Oct 2024
Viewed by 333
Abstract
Background/Objectives: Melanoma is an aggressive skin malignancy, and the majority of deaths associated with melanoma result from malignant skin lesions. Our study aims to evaluate the expression of the markers CD133 and NANOG, associated with tumor stem cells, and to analyze their [...] Read more.
Background/Objectives: Melanoma is an aggressive skin malignancy, and the majority of deaths associated with melanoma result from malignant skin lesions. Our study aims to evaluate the expression of the markers CD133 and NANOG, associated with tumor stem cells, and to analyze their link with epidemiological and histological parameters, thus contributing to early diagnosis and the development of targeted therapies. Methods: We performed a retrospective study in the Mureș Clinical County Hospital, Romania, which included 66 cases of melanoma: 50 primary cutaneous melanomas, 10 metastases, and 6 local recurrences. CD133 and NANOG marker expression was assessed by immunohistochemistry and quantified using the H score. Statistical analyses were applied to determine the correlations between marker expression and clinicopathological parameters. Results: CD133 expression was identified in six cases (12%) of primary melanoma, with a mean H-Score of 29, and was associated with an increased Breslow index and a higher number of mitoses. NANOG expression was positive in 30 cases (60%) of primary melanoma, with a median H-Score of 15 and with increased expression observed in cases with pagetoid migration and lesions in situ. In metastases, eight cases (80%) were positive for NANOG and four (40%) for CD133. Local recurrences showed positive expression for NANOG in four cases (66%). Conclusions: The expression of CD133 and NANOG markers highlights the role of tumor stem cells in melanoma progression. Early identification of these markers could improve diagnosis and treatment, including the application of targeted therapies. Full article
(This article belongs to the Special Issue Advances in the Diagnosis, Prevention and Treatment of Skin Tumors)
Show Figures

Figure 1

Back to TopTop